Filing Overview
Olema Pharmaceuticals, Inc. filed a Form 8-K dated January 8, 2024, under Item 7.01 (Regulation FD Disclosure) and Item 9.01. The company furnished an investor presentation dated January 8, 2024, as Exhibit 99.1. The presentation was made available on the company’s website for sharing with investors and others.
Business Context and Reporting Period
Olema Pharmaceuticals is a Delaware corporation headquartered in San Francisco, California, trading on the Nasdaq Global Select Market under the symbol OLMA. This filing is not a periodic financial report and does not cover a stated quarterly or annual reporting period.
Financial Metrics
The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash runway, or other financial metrics. The contents of Exhibit 99.1 were not included in the provided filing text.
Material Changes Versus Prior Period
No material financial or operational changes versus a prior comparable period are disclosed in the filing text.
Guidance, Outlook, Risks, and Unusual Items
- The filing furnishes an investor presentation but does not state specific guidance, forecasts, milestones, risks, contingencies, or unusual items in the provided text.
- Exhibit 99.1 is furnished, rather than filed, and is not deemed subject to the liabilities of Section 18 of the Exchange Act or incorporated by reference into other filings, except where expressly referenced.
Investor Verification Items
- Review Exhibit 99.1 and the company’s website for any clinical, regulatory, financial, cash runway, or pipeline disclosures contained in the investor presentation.
- Verify whether the presentation includes updated development timelines, trial results, financing needs, or corporate milestones.
- Confirm that no financial statements or other periodic-report disclosures were intended to be provided by this Form 8-K.